PYRIMIDINSULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS, METHODS OF THEIR OBTAINING (VERSIONS) AND APPLICATION Russian patent published in 2008 - IPC C07D239/48 C07D239/69 C07D401/12 C07D403/12 C07D405/12 C07D409/12 C07D413/12 C07D413/14 C07D417/12 A61K31/506 A61K31/5377 A61P11/00 A61P29/00 A61P35/00 

FIELD: chemistry, pharmacology.

SUBSTANCE: invention relates to novel compounds of formula (I), its pharmaceutically acceptable salts, possessing qualities of chemokine receptor modulators. Compounds can be applied for asthma, allergic rhinitis, COLD, inflammatory intestinal disease, irritated intestine syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis or cancer. In compound of formula (I) , R¹ represents group selected from C_1-8alkyl, said group is possibly substituted with 1, 2 or 3 substituents, independently selected from -OR⁴ , -NR⁵R⁶ , phenyl, phenyl is possibly substituted with 1, 2 or 3 substituents, independently selected from halogeno, -OR⁴,-NR⁵R⁶,-SR¹⁰,C_1-6alkyl and trifluoromethyl; R² represents group selected from C_1-8alkyl, said group is substituted with 1, 2 or 3 substituents, independently selected from hydroxy, amino, C_1-6alkoxy, C_1-6alkylamino, di(C_1-6alkyl)amino, N-(C_1-6alkyl)-N-(phenyl)amino; R³ represents hydrogen, R⁴ represents hydrogen or group selected from C_1-6alkyl and phenyl, R⁵ and R⁶, independently, represent hydrogen or group selected from C_1-6alkyl and phenyl, said group being probably substituted with 1, 2 or 3 substituents, independently selected from -OR¹⁴, -NR¹⁵R¹⁶, -COOR¹⁴,-CONR¹⁵R¹⁶, or R⁵ and R⁶ together with nitrogen atom, to which they are bound, form 4-7-member saturated heterocyclic ring system, possibly containing additional heteroatom, selected from oxygen and nitrogen atoms, ring possibly being substituted with 1, 2 or 3 substituents, independently selected from -OR¹⁴, -COOR¹⁴,-NR¹⁵R¹⁶ _,CONR¹⁵R¹⁶ and C_1-6alkyl; R¹⁰ represents hydrogen or group selected from C_1-6alkyl or phenyl; and each from R⁷, R⁸, R⁹, R¹⁴, R¹⁵, R¹⁶ independently represents hydrogen, C_1-6alkyl or phenyl; X represents hydrogen, halogeno; R^x represents trifluoromethyl, -NR⁵ R⁶ , phenyl, naphtyl, heteroaryl, heteroring can be partly or fully saturated, and one or more ring carbon atoms can form carbonyl group, each phenyl or heteroaryl group being possibly substituted with 1, 2 or 3 substituents, independently selected from halogeno, cyano, -OR⁴, -NR⁵R⁶, -CONR⁵R⁶, -COR⁷, -COOR⁷, -NR⁸COR⁹, -SR¹⁰, -SO₂R¹⁰, -SO₂NR⁵R⁶, -NR⁸SO₂R⁹, C_1-6alkyl or trifluoromethyl; or R^x represents group selected from C_1-6alkyl, said group being possibly substituted with 1, 2 or 3 substituents, independently selected from halogeno, -OR⁴, -NR⁵R⁶, phenyl or heteroaryl, where heteroaryl represents monocyclic or bicyclic aryl ring, containing from 5 to 10 ring atoms, from which 1, 2 or 3 ring atoms are selected from nitrogen, sulfur or oxygen. Invention also relates to methods of obtaining compounds, versions, pharmaceutical composition and application for manufacturing medications using compounds of invention.

EFFECT: obtaining novel compounds of formula (I), its pharmaceutically acceptable salts, possessing properties of chemokine receptor moduators.

25 cl, 138 ex